Endpoints News 生物医药· Max Gelman·· 11 天前AI 评分23
Zura Bio 报告 II 期临床失败,股价暴跌
Zura reports Phase 2 flop in painful skin disorder, stock nosedives
AI 导读
Zura Bio 报告其在治疗一种顽固皮肤疾病的 II 期临床试验中失败,公司股价大幅下跌。
正文
A small biotech’s stock collapsed after the company reported a Phase 2 failure in a debilitating skin condition.
Zura Bio said Monday morning that both …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
来源:Endpoints News 生物医药 · endpoints.news